Tumor volume reduction after neoadjuvant chemotherapy in childhood nephroblastoma: radiological, histopathological, and clinical correlates in Tanzania

Pediatric Hematology Oncology Journal Pub Date : 2026-06-01 Epub Date: 2026-05-19 DOI:10.1016/j.phoj.2026.100836
Tumaini Mtui , Clement Kalambo , Esther Majaliwa , Heronima Kashaigili , Vincent Odhiambo , Felister Uisso , Adnan Sadiq
{"title":"Tumor volume reduction after neoadjuvant chemotherapy in childhood nephroblastoma: radiological, histopathological, and clinical correlates in Tanzania","authors":"Tumaini Mtui ,&nbsp;Clement Kalambo ,&nbsp;Esther Majaliwa ,&nbsp;Heronima Kashaigili ,&nbsp;Vincent Odhiambo ,&nbsp;Felister Uisso ,&nbsp;Adnan Sadiq","doi":"10.1016/j.phoj.2026.100836","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Nephroblastoma is the most common pediatric kidney cancer, accounting for approximately 6% of childhood malignancies. Neoadjuvant chemotherapy plays an important role in reducing tumor size and facilitating safer surgery. This study aimed to determine radiological tumor volume reduction in nephroblastoma after neoadjuvant chemotherapy and its associations with histopathological subtypes and clinical outcomes among children in a lower-middle income country (Tanzania).</div></div><div><h3>Material and methods</h3><div>A retrospective cohort study was conducted among 126 children aged 6 months to &lt;18 years with histopathologically confirmed nephroblastoma treated under the International Society of Pediatric Oncology (SIOP) umbrella protocol diagnosed at two tertiary oncology centers in Tanzania between Jan. 2021 and Dec. 2023. Tumor volumes were measured from pre- and post-neoadjuvant chemotherapy abdominal pelvic computed tomography scans to calculate volume reduction ratios. SPSS v26 was used for analysis, with logistic regression and chi-square tests used to assess associations with histopathology and clinical outcomes.</div></div><div><h3>Results</h3><div>The median age at diagnosis was 36 months, with female predominance (57.9%), and most lacked health insurance (71.4%). Blastemal histological subtype was the most common subtype (40.5%). Post neoadjuvant chemotherapy, 62.7% of patients achieved a good response, while 40.5% had residual tumor volumes &gt;500 ml. Stromal histology was strongly associated with large residual (AOR = 15.00; 95% CI: 4.00–56.13; p &lt; 0.001). Tumor volume reduction also varied by treatment center and insurance status.</div></div><div><h3>Conclusion</h3><div>Histopathological subtypes are key determinants of the radiological response following neoadjuvant chemotherapy. Differences by treatment center and insurance status suggest that healthcare-related factors also influence outcomes, although the treatment center effect showed borderline statistical significance. Further large-scale studies are needed to clarify these associations in resource-limited settings.</div></div>","PeriodicalId":101004,"journal":{"name":"Pediatric Hematology Oncology Journal","volume":"11 2","pages":"Article 100836"},"PeriodicalIF":0.0000,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pediatric Hematology Oncology Journal","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2468124526000343","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/5/19 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Nephroblastoma is the most common pediatric kidney cancer, accounting for approximately 6% of childhood malignancies. Neoadjuvant chemotherapy plays an important role in reducing tumor size and facilitating safer surgery. This study aimed to determine radiological tumor volume reduction in nephroblastoma after neoadjuvant chemotherapy and its associations with histopathological subtypes and clinical outcomes among children in a lower-middle income country (Tanzania).

Material and methods

A retrospective cohort study was conducted among 126 children aged 6 months to <18 years with histopathologically confirmed nephroblastoma treated under the International Society of Pediatric Oncology (SIOP) umbrella protocol diagnosed at two tertiary oncology centers in Tanzania between Jan. 2021 and Dec. 2023. Tumor volumes were measured from pre- and post-neoadjuvant chemotherapy abdominal pelvic computed tomography scans to calculate volume reduction ratios. SPSS v26 was used for analysis, with logistic regression and chi-square tests used to assess associations with histopathology and clinical outcomes.

Results

The median age at diagnosis was 36 months, with female predominance (57.9%), and most lacked health insurance (71.4%). Blastemal histological subtype was the most common subtype (40.5%). Post neoadjuvant chemotherapy, 62.7% of patients achieved a good response, while 40.5% had residual tumor volumes >500 ml. Stromal histology was strongly associated with large residual (AOR = 15.00; 95% CI: 4.00–56.13; p < 0.001). Tumor volume reduction also varied by treatment center and insurance status.

Conclusion

Histopathological subtypes are key determinants of the radiological response following neoadjuvant chemotherapy. Differences by treatment center and insurance status suggest that healthcare-related factors also influence outcomes, although the treatment center effect showed borderline statistical significance. Further large-scale studies are needed to clarify these associations in resource-limited settings.
坦桑尼亚儿童肾母细胞瘤新辅助化疗后肿瘤体积减小:放射学、组织病理学和临床相关性
肾母细胞瘤是最常见的儿童肾癌,约占儿童恶性肿瘤的6%。新辅助化疗在缩小肿瘤大小和促进手术安全性方面起着重要作用。本研究旨在确定中低收入国家(坦桑尼亚)儿童肾母细胞瘤新辅助化疗后的放射学肿瘤体积减少及其与组织病理学亚型和临床结果的关系。材料和方法一项回顾性队列研究对126名6个月至18岁的儿童进行了研究,这些儿童在2021年1月至2023年12月期间在坦桑尼亚的两个三级肿瘤中心诊断,经组织病理学证实,接受国际儿科肿瘤学会(SIOP)总方案治疗。通过新辅助化疗前后腹部盆腔计算机断层扫描测量肿瘤体积,计算体积缩小比。采用SPSS v26进行分析,采用logistic回归和卡方检验评估与组织病理学和临床结果的相关性。结果确诊年龄中位数为36个月,女性占57.9%,无医疗保险者占71.4%。胚质组织学亚型是最常见的亚型(40.5%)。新辅助化疗后,62.7%的患者获得了良好的反应,40.5%的患者肿瘤残留体积为500 ml。基质组织学与肿瘤残留较大密切相关(AOR = 15.00; 95% CI: 4.00-56.13; p < 0.001)。肿瘤体积减少也因治疗中心和保险状况而异。结论组织病理学亚型是新辅助化疗后放射反应的关键决定因素。治疗中心和保险状况的差异表明,医疗保健相关因素也会影响结果,尽管治疗中心效应具有临界统计学意义。在资源有限的情况下,需要进一步的大规模研究来澄清这些关联。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.00
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书